SBIR-STTR Award

Development of a Rapid Screening Point-Of-Care Test for Hiv, Hcv and Hbv
Award last edited on: 9/20/13

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$145,915
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Stephen R Lee

Company Information

OraSure Technologies Inc (AKA: Epitope Inc ~ Immunologic Associates, Inc ~ STC Technologies)

220 East First Street
Bethlehem, PA 18015
   (610) 882-1820
   preis@orasure.com
   www.orasure.com
Location: Multiple
Congr. District: 07
County: Northampton

Phase I

Contract Number: 1R44AI096758-01A1
Start Date: 7/17/12    Completed: 6/30/13
Phase I year
2012
Phase I Amount
$145,915
The objective of this research application is the development of a simple, highly portable test system for rapid screening for human immunodeficiency virus (HIV) and hepatitis at the point of care (POC). This test system will be capable of identifying patients infected by HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV) in a small drop of blood obtained by finger stick. This will allow the use of this test syste in settings such as physician offices, public health testing clinics, community outreach centers and mobile testing facilities. It is the intention to obtain regulatory approvals in the US, such tat this system can be used outside of traditional laboratory settings by individuals with minimal training. This will enable maximum access to populations at greatest risk for HIV and hepatitis. It is expected that by enabling increased testing of high risk populations, a higher proportion of infected individuals will be diagnosed and gain earlier access to appropriate medical treatment. The test system will consist of test cartridges specific for each disease state and a simple-to-use instrument providing objective results to the user. Use of manual, rapid tests has previously been shown to be effective in increasing diagnosis of HIV. Currently, approximately 25% of HIV infection and more than half of the cases of HCV and HBV infection are undiagnosed. This reservoir of undiagnosed infection represents a growing burden of mortality and morbidity and also contributes to greater transmission rates within the population. Improved therapeutic outcomes in infected individuals who are treated earlier in the course of disease are now well documented. Improved the rapid tests for treatment of HCV were recently approved in the US and reduction of future morbidity and mortality will be highly dependent on expanded testing and diagnoses. Additionally, early treatment of HIV infected individuals has been shown to greatly reduce the risk of disease transmission. Increased testing and treatment of individuals infected with these blood borne viruses will significantly improve health outcomes in infected individuals and reduce transmission through reduction of community viral burden.

Public Health Relevance:
The purpose of this project is to develop a new and proprietary system that can detect the presence of infection by HIV, hepatitis B or hepatitis C from a small drop of finger-stick blood. This will expand testing opportunities, increase disease diagnoses and enable more individuals to become more aware of their status and thus receive earlier intervention in the course of disease. This will result in improved health care outcomes; reduced disease transmission, as well as reducing overall medical costs.

Public Health Relevance Statement:
The purpose of this project is to develop a new and proprietary system that can detect the presence of infection by HIV, hepatitis B or hepatitis C from a small drop of finger-stick blood. This will expand testing opportunities, increase disease diagnoses and enable more individuals to become more aware of their status and thus receive earlier intervention in the course of disease. This will result in improved health care outcomes; reduced disease transmission, as well as reducing overall medical costs.

NIH Spending Category:
Bioengineering; Chronic Liver Disease and Cirrhosis; Clinical Research; Digestive Diseases; Emerging Infectious Diseases; HIV/AIDS; Health Services; Hepatitis; Hepatitis - B; Hepatitis - C; Infectious Diseases; Liver Disease; Prevention

Project Terms:
anti-hepatitis C; Antibodies; Antigens; base; Bedside Testings; Biological Assay; Blood; burden of illness; Clinic; Clinical; Communities; Community Outreach; cost; design; Detection; Development; Devices; Diagnosis; Disease; disease diagnosis; disease transmission; Drops; Early treatment; FDA approved; Fingers; Fluorescence; Future; Goals; Health; Healthcare; Hepatitis; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Virus; Hepatitis C; Hepatitis C virus; high risk; HIV; Hospitals; human subject; improved; Individual; Infection; instrument; Intention; Label; Laboratories; Laboratory Study; Manuals; Medical; Morbidity - disease rate; Mortality Vital Statistics; Outcome; particle; Patients; Performance; Phase; Physicians' Offices; point of care; Population; Populations at Risk; portability; Production; prospective; prototype; public health medicine (field); Reader; Research; Risk; Screening procedure; Sensitivity and Specificity; Small Business Innovation Research Grant; Specimen; Speed (motion); System; Testing; Therapeutic; Therapeutic Intervention; Training; transmission process; United States; Viral Load result; Virus; Virus Diseases

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----